Abstract
A nucleus-specific RNAi nanoplatform was developed by Xu et al. for targeted regulation of nuclear lncRNA function and effective cancer therapy. This nanoplatform could respond to the endosomal pH to expose NTPA/siRNA complexes for the nucleus-specific siRNA delivery, leading to a significant inhibition of nuclear lncNEAT2 expression and tumor growth.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
